
FDA requests removal of suicidal ideation warnings from GLP-1 receptor agonist labeling after a comprehensive review found no increased risk.

FDA requests removal of suicidal ideation warnings from GLP-1 receptor agonist labeling after a comprehensive review found no increased risk.
Psychiatrist Gus Alva, MD, discusses newer, faster depression screening approaches that primary care clinicians can implement.

Your daily dose of the clinical news you may have missed.

Weight-loss interventions significantly enhance psoriasis severity and quality of life, emphasizing their role in effective psoriasis management strategies.

Your daily dose of the clinical news you may have missed.
.jpg?w=350&fit=crop&auto=format)
FDA identifies deficiencies in Anaphylm's NDA, impacting labeling discussions, while review continues for this innovative treatment for severe allergic reactions.

Your daily dose of the clinical news you may have missed.
A nephrology expert reviews how workflow constraints and care delivery pressures affect adherence to guideline-recommended responses to elevated urine albumin-to-creatinine ratio.

The AHA and ACC commend the focus on fruits, vegetables, and whole grains but caution against high-fat dairy and protein emphasis.

New data from the DROP-AD study suggests that dried blood spots could revolutionize screening approaches for clinical trials.

Your daily dose of the clinical news you may have missed.

COVID-19 vaccination before infection significantly reduces hospitalization, critical care admissions, and preterm birth rates in pregnant individuals, study finds.

Your daily dose of the clinical news you may have missed.
.jpg?w=350&fit=crop&auto=format)
FDA prioritizes review of Tzield for young children with stage 2 type 1 diabetes, potentially delaying disease onset and improving patient outcomes.

Your daily dose of the clinical news you may have missed.
.jpg?w=350&fit=crop&auto=format)
The FDA has accepted a supplemental NDA for AXS-05 for agitation associated with Alzheimer disease and granted Priority Review, with a PDUFA action date of April 30, 2026.

Take a quick look back at developments this year with our higlights of acceleration of DMTs, particularly focusing on anti-amyloid antibodies and novel oral agents.

Clevenger explains how better recognition of agitation in Alzheimer disease, and stronger caregiver–clinician communication, can meaningfully improve outcomes.